Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution that contains the active ingredient glucose. It is supplied in a sterile liquid form for parenteral administration, with the specific concentration not disclosed in the public data. Marketed in the European Union and available by prescription, this product functions as an energy source when infused directly into the bloodstream. It is classified as an excipient rather than a therapeutic drug.

Glucose Viaflo Baxter is used in clinical settings where rapid provision of carbohydrate energy is required.

- To maintain blood glucose levels during fasting or prolonged surgery. - As part of fluid resuscitation in patients with hypoglycemia. - To provide caloric support in critically ill patients receiving total parenteral nutrition. - In neonatal intensive care for infants with low blood glucose. - As a diluent for compatible intravenous medications when glucose is needed as a carrier. - To assist in the administration of certain electrolytes that require a glucose-containing carrier solution.

When administered intravenously, glucose solutions can be associated with a range of physiological responses that are reported as side effects.

Common: - Transient hyperglycemia that resolves after the infusion ends. - Mild irritation at the infusion site. - Electrolyte shifts, particularly a decrease in serum potassium. - Temporary increase in blood osmolality that normalizes after infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypoglycemia after abrupt discontinuation in patients with impaired glucose regulation. - Fluid overload in patients with compromised cardiac or renal function. - Risk of infection if aseptic technique is not maintained during preparation or administration. - Development of hyperosmolar hyperglycemic state in patients with uncontrolled diabetes.

Glucose Viaflo Baxter should be administered with attention to patient-specific factors and standard infusion safety practices.

- Verify blood glucose concentration before and after infusion to avoid extreme values. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use a dedicated intravenous line or compatible carrier to reduce incompatibility risks. - Monitor electrolytes, especially potassium and sodium, during and after administration. - Avoid rapid bolus administration unless clinically indicated, as it may cause sudden hyperglycemia. - Document the product name, concentration, and total volume administered in the patient record.

Glucose solutions can interact with other intravenous agents, and certain combinations require special consideration.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate calcium gluconate. - Simultaneous infusion with sodium bicarbonate solutions, which can raise solution pH and cause precipitation.

Use with caution: - Concurrent use with potassium chloride infusions; monitor serum potassium closely. - Administration alongside diuretics that affect fluid balance; adjust volume as needed. - Use with medications that have a high osmolarity, as combined osmotic load may increase risk of vascular irritation. - Use with blood products that require a specific glucose concentration; verify compatibility before mixing.